310 related articles for article (PubMed ID: 23265382)
21. HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound.
Claros OR; Tourinho-Barbosa RR; Carneiro A; Collura-Merlier S; Macek P; Lanz C; Cathala N; Prapotnich D; Mombet A; Sanchez-Salas R; Cathelineau X
Arch Esp Urol; 2019 Oct; 72(8):825-830. PubMed ID: 31579041
[TBL] [Abstract][Full Text] [Related]
22. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer.
Williams AK; Martínez CH; Lu C; Ng CK; Pautler SE; Chin JL
Eur Urol; 2011 Sep; 60(3):405-10. PubMed ID: 21185115
[TBL] [Abstract][Full Text] [Related]
23. Targeted focal therapy for the management of organ confined prostate cancer.
Barqawi AB; Stoimenova D; Krughoff K; Eid K; O'Donnell C; Phillips JM; Crawford ED
J Urol; 2014 Sep; 192(3):749-53. PubMed ID: 24641910
[TBL] [Abstract][Full Text] [Related]
24. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
25. Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry.
Blana A; Robertson CN; Brown SC; Chaussy C; Crouzet S; Gelet A; Conti GN; Ganzer R; Pasticier G; Thuroff S; Ward JF
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):256-9. PubMed ID: 22487909
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
27. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology.
Pinthus JH; Farrokhyar F; Hassouna MM; Woods E; Whelan K; Shayegan B; Orovan WL
BJU Int; 2012 Oct; 110(8):1142-8. PubMed ID: 22372721
[TBL] [Abstract][Full Text] [Related]
28. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
29. High intensity focused ultrasound with Focal-One
Perez-Reggeti JI; Sanchez-Salas R; Sivaraman A; Linares Espinos E; de Gracia-Nieto AE; Barret E; Galiano M; Rozet F; Fregeville A; Renard-Penna R; Cathala N; Mombet A; Prapotnich D; Cathelineau X
Actas Urol Esp; 2016 Dec; 40(10):608-614. PubMed ID: 27543259
[TBL] [Abstract][Full Text] [Related]
30. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer.
Williams SB; Lei Y; Nguyen PL; Gu X; Lipsitz SR; Yu HY; Kowalczyk KJ; Hu JC
BJU Int; 2012 Jul; 110(2 Pt 2):E92-8. PubMed ID: 22192688
[TBL] [Abstract][Full Text] [Related]
32. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
Lilleby W; Tafjord G; Raabe NK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
[TBL] [Abstract][Full Text] [Related]
33. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
34. [High-intensity focused ultrasound (HIFU) for the prostate cancer treatment: 5-year resuts].
Shaplysin LV; Solov VA; Vosdvizhenskiĭ MO; Khametov RZ
Urologiia; 2013; (1):70-2. PubMed ID: 23662500
[TBL] [Abstract][Full Text] [Related]
35. Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.
Inoue Y; Goto K; Hayashi T; Hayashi M
Int J Urol; 2011 May; 18(5):358-62. PubMed ID: 21449970
[TBL] [Abstract][Full Text] [Related]
36. Focal therapy in the treatment of localised prostate cancer: primum non nocere.
Challacombe BJ; Murphy DG
Eur Urol; 2013 Apr; 63(4):623-4; discussion 625-6. PubMed ID: 23290301
[No Abstract] [Full Text] [Related]
37. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
38. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
39. Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center.
Elterman DS; Barkin J; Radomski SB; Fleshner NE; Liu B; Bensimon K; Arora S; Robinette M; Finelli A
Can J Urol; 2011 Dec; 18(6):6037-42. PubMed ID: 22166332
[TBL] [Abstract][Full Text] [Related]
40. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
